The North America HIV Diagnostics Market size was valued at USD 880 million in 2025 and is expected to reach USD 1,430 million by 2035, at a CAGR of 4.9% from 2024 to 2035. The market is driven by technological advances and rising awareness, with robust competition among leading diagnostic companies.
The economic impact of tariffs on "North America HIV Diagnostics Market".
Market Growth Drivers
Technological Advancements in Rapid Testing: Companies such as Abbott Laboratories have significantly improved rapid HIV diagnostic platforms, making high-precision, user-friendly, and cost-effective tests readily available in clinical and non-clinical settings. This accessibility supports earlier diagnosis and treatment, driving market expansion.
Government Initiatives & Funding: Programs like the U.S. federal Ending the HIV Epidemic initiative boost the adoption of diagnostic tests. Companies like Bio-Rad Laboratories collaborate with public health agencies, leveraging increased funding to deploy innovative diagnostic solutions and screening campaigns, particularly in at-risk communities.
Market Trends
Adoption of Self-Testing Kits: Leading players including OraSure Technologies are launching next-generation self-test kits that combine digital interfaces for result tracking and telehealth support. This caters to privacy-conscious consumers, improves test uptake, and enables rapid surveillance data collection for public health authorities.
Integration of Artificial Intelligence (AI): Companies such as Roche Diagnostics are implementing AI-driven analytics with their lab systems to enhance early HIV detection, reduce diagnostic errors, and optimize clinical workflow efficiency. This digital transformation aids clinicians while improving patient outcomes.
Market Opportunities
Expansion in Untapped Rural Markets: Firms like Siemens Healthineers have opportunities for growth by customizing outreach and partnerships with local clinics in underserved areas, deploying mobile health units and innovative rapid diagnostics.
Strategic Collaborations with Digital Health Startups: Large diagnostics companies are collaborating with health-tech startups to integrate HIV testing data into digital health records, increasing patient engagement and providing new value-based care opportunities.
North America HIV Diagnostics Market Revenue (USD Million), 2020-2035
The revenue chart shows a steady upward trend, with the market valued at USD 670 million in 2020. Growth accelerates from 2022 onward, driven by increased adoption of rapid and AI-assisted diagnostics. By 2025, the market reaches USD 880 million. Afterward, expanding into digital and rural health channels sustains the annual market growth, pushing revenues to USD 1,430 million by 2035. This consistent CAGR of 4.9% reflects technological innovation, recurring demand for HIV testing, and new product launches by key market players.
North America HIV Diagnostics Market by Region, 2025 (%)
The pie chart indicates the United States dominates the market, accounting for 76% owing to advanced healthcare infrastructure and funding. Canada follows with 16%, benefitting from universal healthcare coverage and rising awareness. Mexico captures 6% due to increasing test adoption in urban centers. The Caribbean and Central America, though less prominent within North America, account for 1% each, reflecting market penetration primarily through public health initiatives and international aid programs.
Recent Developments in the North America HIV Diagnostics Market (Past 6 Months)
In February 2024, Roche Diagnostics announced the launch of its new 'cobas HIV-1/2' dual assay in the U.S., offering simultaneous detection and improved sensitivity. The dual assay claims reduced window periods and better detection rates for diverse HIV subtypes compared to legacy platforms—strengthening Roche’s market share amid rising molecular diagnostics demand.
In April 2024, Abbott Laboratories secured FDA clearance for their Alinity m HIV-1 Genotype Resistance Testing, a crucial tool to optimize patient therapy, reduce drug resistance risk, and support clinicians in tailoring antiretroviral regimens. This launch marks Abbott’s key milestone in precision diagnostics, addressing the evolving needs of HIV care.
In June 2024, Bio-Rad Laboratories announced a partnership with several U.S. state health departments to deploy next-generation, AI-enabled HIV diagnostic instruments in public health labs. These systems are designed for high-throughput environments, facilitating rapid community-level screening and advanced epidemiological surveillance.
By Type: Antibody Tests, Viral Load Tests, CD4 Tests, Early Infant Diagnosis, Nucleic Acid Tests (NAT), Others; By Application: Diagnostic Laboratories, Hospitals, Blood Banks, Home Care Settings, Research Institutes, Others
Press Releases